Status:
COMPLETED
Scotoma Reduction in AMD Patients Treated With Ranibizumab
Lead Sponsor:
Retina Research Foundation
Conditions:
Macular Degeneration
Eligibility:
All Genders
50-90 years
Phase:
PHASE1
PHASE2
Brief Summary
This is a trial aimed at patients with advanced wet macular degeneration and macular scarring treated wiht intravitreal injections of Lucentis.
Detailed Description
Patients with severe wet macular degeneration and scarring in the center of the retina may benefit from treatment if the size of the blind spot is reduced wiht injections of Lucentis.
Eligibility Criteria
Inclusion
- BCVA \< 20/320
- Disciform macular degeneration wiht exudation
Exclusion
- Non-amd CNV
Key Trial Info
Start Date :
March 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
November 1 2007
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT00467935
Start Date
March 1 2007
End Date
November 1 2007
Last Update
July 29 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Retina Research Center
Slingerlands, New York, United States, 12159